Ciencias Económicas y Empresariales
Facultad
![Foto de Ciencias Económicas y Empresariales](/img/uploaded/13EC7F3EC186245E486AB981CF055011.jpg)
![Foto de Complexo Hospitalario Universitario de Santiago](/img/noimage_org.png)
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (17)
2020
2019
2018
-
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
Targeted Oncology, Vol. 13, Núm. 1, pp. 69-78
-
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients (Targeted Oncology, (2018), 13, 1, (69-78), 10.1007/s11523-017-0536-z)
Targeted Oncology
-
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Breast Cancer Research and Treatment, Vol. 169, Núm. 3, pp. 469-479
-
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial
Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3126-3133
2017
-
Assessment of HER2 status in resected gastric cancer in European population
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, pp. iii15
2016
-
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366
-
Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
Annals of Oncology, Vol. 27, pp. vi68
-
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
Oncotarget, Vol. 7, Núm. 25, pp. 37680-37692
-
Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
Melanoma Research, Vol. 26, Núm. 3, pp. 278-283
2015
-
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: Results of the PANCOSTABRAX study
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 4, pp. 579-589
-
Erratum: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study [Support Care Cancer, DOI 10.1007/s00520-015-2809-3]
Supportive Care in Cancer
-
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Supportive Care in Cancer, Vol. 23, Núm. 9, pp. 2833-2840
-
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer
Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 731-737
2012
-
Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: A report of three cases
Medical Oncology, Vol. 29, Núm. 2, pp. 795-798
2010
-
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
British Journal of Cancer, Vol. 103, Núm. 10, pp. 1536-1541